FDA Pauses Verve’s Trial Plan for Gene-Editing Therapy for High Cholesterol

💡 This post was automatically imported from MedCity News. You can find the original article here.
Author: Frank Vinluan

Image of heart and circulatory system

The FDA placed a clinical hold on Verve Therapeutics’ application to begin human testing of its gene-editing therapy for an inherited form of high cholesterol. No details about the FDA’s questions or concerns were disclosed; so far, no serious safety problems have been reported in the U.K. and New Zealand where the clinical trial is already underway.

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

Welcome to MediFormatica. The site is still under construction so there are some rough edges here and there, but I'll be adding new and exciting content every day. So enjoy it and come back again for more great stuff.